Title: Potent and Highly Selective Aldo-Keto Reductase 1C3 (AKR1C3) Inhibitors Act as Chemotherapeutic Potentiators in Acute Myeloid Leukemia and T-Cell Acute Lymphoblastic Leukemia.
Authors: Verma, Kshitij; Zang, Tianzhu; Penning, Trevor M; Trippier, Paul C
Published In J Med Chem, (2019 04 11)
Abstract: Aldo-keto reductase 1C3 (AKR1C3) catalyzes the synthesis of 9α,11β-prostaglandin (PG) F2α and PGF2α prostanoids that sustain the growth of myeloid precursors in the bone marrow. The enzyme is overexpressed in acute myeloid leukemia (AML) and T-cell acute lymphoblastic leukemia (T-ALL). Moreover, AKR1C3 confers chemotherapeutic resistance to the anthracyclines: first-line agents for the treatment of leukemias. The highly homologous isoforms AKR1C1 and AKR1C2 inactivate 5α-dihydrotestosterone, and their inhibition would be undesirable. We report herein the identification of AKR1C3 inhibitors that demonstrate exquisite isoform selectivity for AKR1C3 over the other closely related isoforms to the order of >2800-fold. Biological evaluation of our isoform-selective inhibitors revealed a high degree of synergistic drug action in combination with the clinical leukemia therapeutics daunorubicin and cytarabine in in vitro cellular models of AML and primary patient-derived T-ALL cells. Our developed compounds exhibited >100-fold dose reduction index that results in complete resensitization of a daunorubicin-resistant AML cell line to the chemotherapeutic and >100-fold dose reduction of cytarabine in both AML cell lines and primary T-ALL cells.
PubMed ID: 30836001
MeSH Terms: Aldo-Keto Reductase Family 1 Member C3/antagonists & inhibitors*; Antineoplastic Agents/chemistry; Antineoplastic Agents/pharmacology; Antineoplastic Agents/therapeutic use*; Cell Line, Tumor; Cytarabine/administration & dosage; Daunorubicin/administration & dosage; Drug Synergism; Enzyme Inhibitors/chemistry; Enzyme Inhibitors/pharmacology; Enzyme Inhibitors/therapeutic use*; Humans; Leukemia, Myeloid, Acute/drug therapy*; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma/drug therapy*; Structure-Activity Relationship